Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

February 28, 2017

Conditions
Locally Advanced Malignant NeoplasmOral CancerOropharyngeal CarcinomaEffects of Chemotherapy
Interventions
DRUG

Neo-adjuvant Erbitux-based chemotherapy

"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"

Trial Locations (1)

200011

Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Tongji University

OTHER

collaborator

Second Military Medical University

OTHER

lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT01434394 - Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer | Biotech Hunter | Biotech Hunter